Abstracts tagged "vaccines and viruses"

Abstract Number: 1439 • 2018 ACR/ARHP Annual Meeting
Yellow Fever Vaccination in Brazil: Short-Term Safety in Pediatric Autoimmune Rheumatic Diseases
Nadia E Aikawa¹, Verena A Balbi², Adriana C Tonacio³, Adriana M E Sallum², Lucia M A Campos², Katia T. Kozu², Margarete B Vendramini¹, Nicole Fontoura¹, Ana MC Sartori⁴, Leila Antonangelo⁵, Clovis A Silva² and Eloisa Bonfa⁶, ¹Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ²Pediatric Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Infectology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Infectology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁵Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Yellow fever (YF) immunization is not routinely performed in juvenile autoimmune rheumatic disease (ARD) patients. However, during the recent epidemic campaign in state of…
Abstract Number: 605 • 2012 ACR/ARHP Annual Meeting
Increased Incidence of Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Eliza F. Chakarvarty¹, Kaleb Michaud², Robert S. Katz³ and Frederick Wolfe⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, ²Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ³Rush University Medical Center, Chicago, IL, ⁴National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Herpes zoster (HZ) is the painful reactivation of latent varicella zoster virus infection. The incidence of HZ may be increased in some autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].